Oncoptpeptides - Bring hope through science

Bringing hope through science

Webcast - presentation of OCEAN data presented at IMW

Oncopeptides presented data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media were invited to participate in a webcast including a Q&A on September 12 at 16:00 CEST.

The event was hosted by Marty J Duvall, CEO, Klaas Bakker, CMO as well as Fredrik Schjesvold, MD, Head of Oslo Myeloma Center. The presentation was held in English and was recorded.

More info, presentation and the webcast link

Released

Interim report Q2 2021

Launch dynamics encouraging, but US regulatory situation challenging

CEO Marty J Duvall

 

See the Webcast                     See interview in Di.TV


For further information, please contact:

Linda Holmström
Director of Investor Relations

 

Q3 report November 4, 2021

Profile image

Press release -

Oncopeptides presents phase 3 OCEAN study results at the IMW meeting

Read press release
Events Oncopeptides

Upcoming events

View calendar

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Released

Annual Report 2020

“The past year was a transformational year for Oncopeptides  highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”

Marty J Duvall, CEO

 

Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.

 

Annual Report 2020 - online version

 

For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image
Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more